Fed governors may dissent against Powell amid Trump pressure - WSJ’s Timiraos
HONG KONG, SHANGHAI, & FLORHAM PARK, NJ - Hutchmed (China) Limited (Nasdaq/AIM:HCM; HKEX:13) has announced the grant of share options and long-term incentive plan (LTIP) awards to key personnel, including executive directors and additional employees. The grants, made on Monday, aim to incentivize and retain top talent within the organization.
The company granted 1,493,435 share options to Dr. Weiguo Su, Executive Director, CEO, and Chief Scientific Officer, under the Share Option Scheme, with an exercise price of HK$25.50 per ordinary share. These options are subject to performance targets over the fiscal years 2025 to 2027 and will vest following the announcement of the annual results for the year ending December 31, 2027. The specific performance targets, determined by the company’s board, must be met for the options to be exercisable, and unmet targets will result in the lapse of the corresponding options.
In addition to the share options, Hutchmed has also granted LTIP Awards based on maximum cash amounts linked to performance targets for the financial years ending in 2025, 2026, and 2027. Dr. Su has been awarded an LTIP with a maximum value of US$3,442,787, while Mr. Johnny Cheng, Executive Director and CFO, has been awarded a maximum of US$779,934. These awards are dependent on the achievement of strategic objectives and continued employment, with vesting to occur three weeks after the purchase of shares for the 2027 awards.
Following these grants, Hutchmed has 11,409,825 share options available for future issuance under the Share Option Scheme mandate. This move reflects the company’s strategy to align the interests of its key executives with its long-term performance and growth objectives.
Hutchmed is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for cancer and immunological diseases. It has successfully launched three medicines in China, with its first product also approved globally, including in the US, Europe, and Japan.
The information contained in this article is based on a press release statement from Hutchmed (China) Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.